Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.67 |
| ▸ | RET | P07949 | 2/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.67 |
| ▸ | FLT4 | P35916 | 2/20 | 0.67 |
| ▸ | FLT3 | P36888 | 2/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.67 |
| ▸ | GAK | O14976 | 1/20 | 0.67 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.67 |
| ▸ | ERN1 | O75460 | 1/20 | 0.67 |
| ▸ | STK10 | O94804 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.67 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | YES1 | P07947 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296602 | 1.00 | KDR (0.67) | KDRPDGFRBRETCSF1RFLT4 | |
| SCHEMBL15952729 | 0.90 | KDR (0.73) | KDRPDGFRBRETCSF1RFLT4 | |
| SCHEMBL21806025 | 0.88 | KDR (0.69) | KDRPDGFRBRETCSF1RFLT4 | |
| SCHEMBL29902474 | 0.88 | KDR (0.69) | KDRPDGFRBRETCSF1RFLT4 | |
| SCHEMBL1549606 | 0.88 | KDR (0.69) | KDRPDGFRBRETCSF1RFLT4 | |
| SCHEMBL21886103 | 0.87 | KDR (0.70) | KDRPDGFRBRETCSF1RFLT4 | |
| SCHEMBL22779588 | 0.87 | KDR (0.75) | KDRPDGFRBRETCSF1RFLT4 | |
| SCHEMBL16693713 | 0.86 | KDR (0.76) | KDRPDGFRBRETCSF1RFLT4 | |
| SCHEMBL296506 | 0.86 | KDR (0.73) | KDRPDGFRBRETCSF1RFLT4 | |
| SCHEMBL665691 | 0.86 | KDR (0.73) | KDRPDGFRBRETCSF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | claimed |
| EP-1474420-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-03-14 | — | — | EP | claimed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | claimed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | claimed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | claimed |
| US-11713323-B2 | Crystalline forms of therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713323-B2 | Crystalline forms of therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230116686-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | OXFORD FINANCE LLC | 2023-04-13 | — | — | US | disclosed |
| US-11369611-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11369611-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210355133-A1 | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-20210355133-A1 | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2021-11-18 | — | — | US | disclosed |
| WO-2009036055-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080221322-A1 | CHEMICAL PROCESS | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008053221-A2 | PROCESS FOR PREPARING INDOL- 5 -OXY- QUINAZOLINE DERIVATIVES AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | disclosed |
| EP-1474420-A1 | QUINAZOLINE COMPOUNDS | Astrazeneca AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116686-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | KDR 4398/4885PDGFRB 3074/4885RET 2685/4885 |
| US-11713323-B2 | Crystalline forms of therapeutic compounds and uses thereof | AQP3, CFTR, NPC1 | KDR 4668/4885PDGFRB 3212/4885RET 3678/4885 |
| US-11369611-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | KDR 4398/4885PDGFRB 3074/4885RET 2685/4885 |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | VEGFA, FLT4, FLT1 | KDR 4/4885PDGFRB 1557/4885RET 3578/4885 |
| US-20210355133-A1 | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF | AQP3, CFTR, NPC1 | KDR 4668/4885PDGFRB 3212/4885RET 3678/4885 |
| US-20080027069-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | KDR 5/4885PDGFRB 1748/4885RET 2725/4885 |
| US-20080221322-A1 | CHEMICAL PROCESS | CYP3A5, CYP3A4, CYP3A7 | KDR 3684/4885PDGFRB 2428/4885RET 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.